Victoria Chang, MD
Ophthalmology · Naples, FLNPI 1043520109
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,800 of the $8,769 with a category attached, or 66.1%. Johnson & Johnson Surgical Vision, Inc. accounts for 82.6% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2019 at $6,650 and has fallen 91.9% since, to $539 in 2024.
Across 64 payments — averaging $137.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$7K
- Medtronic$363
- Alcon$212
- Glaukos Corporation$176
- Dompe US, Inc.$153
- Oyster Point Pharma, Inc.$147
- plus $474 from 13 others
Across 3 payments — averaging $2497.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Shire North American Group Inc$4K
- Takeda Pharmaceuticals U.S.A., Inc.$4K
What the payments were for
- Consulting fees$5,80066%
- Travel & lodging$3634%
- Food & beverage$2,60630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 28 | $7,245 |
| Medtronic | 2 | $363 |
| Alcon | 6 | $212 |
| Glaukos Corporation | 2 | $176 |
| Dompe US, Inc. | 4 | $153 |
| Oyster Point Pharma, Inc. | 2 | $147 |
| AbbVie | 5 | $88 |
| Rxsight Inc | 1 | $63 |
| Novartis | 2 | $58 |
| Johnson & Johnson Vision Care, Inc. | 1 | $55 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $45 |
| Ocular Therapeutix, Inc. | 2 | $29 |
| Mallinckrodt Enterprises LLC | 1 | $25 |
| Omeros Corporation | 1 | $24 |
| Integra Lifesciences Corporation | 1 | $23 |
| Rayner Intraocular Lenses Limited | 1 | $18 |
| Kala Pharmaceuticals, Inc. | 1 | $16 |
| Amgen | 1 | $15 |
| Halozyme Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Catalys Laser System$6,030
- LigaSure$329
- CATALYS SYSTEM$239
- Tecnis IOL$225
- TYRVAYA$131
- Tecnis Symfony Toric IOL$125
- iStent Trabecular Micro-Bypass System Model iS3$105
- Oxervate$104
- Clareon$102
How this compares
$8,769 in reported general payments places this provider in the 85th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 19 | $24,763 |
| XiidraLifitegrast | 15 | $14,661 |
| Cyclosporine | 12 | $9,626 |
| Loteprednol Etabonate | 18 | $1,930 |
| Prednisolone Acetate | 18 | $578 |
| Doxycycline Hyclate | 25 | $487 |
| ValacyclovirValacyclovir Hcl | 17 | $420 |
| Latanoprost | 23 | $359 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $88 | $24,76319 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $45 | $1,93018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Naples
- Shawn KhanNaples$83K
- Cathleen McCabeBradenton$2M
- Daniel KiernanSarasota$1.7M
- David EichenbaumSt Petersburg$1.7M
- Mark MilnerPalm Beach Gardens$1.2M
- Neel DesaiLargo$1M
- Jorge FortunPalm Beach Gardens$798K
- Courtney BoveeTampa$796K
- Harold BrooksTallahassee$683K
- Robert WeinstockLargo$605K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.